Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis.

Jairath, Vipul; Cohen, Russell D; Loftus, Edward V; Candela, Ninfa; Lasch, Karen; Schultz, Bob G

Jairath, Vipul; Cohen, Russell D; Loftus, Edward V; Candela, Ninfa; Lasch, Karen; Schultz, Bob G.

Afiliação

Jairath V; Western University Schulich School of Medicine, London, ON, Canada.
Cohen RD; University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
Loftus EV; Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Candela N; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave., Lexington, MA, 02421, USA.
Lasch K; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave., Lexington, MA, 02421, USA.
Schultz BG; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave., Lexington, MA, 02421, USA. robert.schultz@takeda.com.

BMC Gastroenterol ; 22(1): 501, 2022 Dec 06.

Article em En | MEDLINE | ID: mdl-36474165

Palavras-chave

Biological products; Cost-effectiveness; Drug safety; Remission; Ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2022 Tipo de documento: Article